{"_buckets": {"deposit": "7ca9d147-d519-4a51-8145-6857ae1aaf86"}, "_deposit": {"id": "2001663", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2001663"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:02001663", "sets": []}, "author_link": [], "control_number": "2001663", "item_1615768549627": {"attribute_name": "\u51fa\u7248\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_9_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "840", "bibliographicPageStart": "827", "bibliographicVolumeNumber": "83", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science", "bibliographic_titleLang": "en"}]}]}, "item_9_description_4": {"attribute_name": "\u5185\u5bb9\u8a18\u8ff0", "attribute_value_mlt": [{"subitem_description": "Tregs infiltrate tumors and inhibit antitumor immunity. KW-0761 (Mogamulizumab) is a humanized anti-CCR4 monoclonal antibody that could eliminate activated Tregs with high immunosuppressive activity that express CCR4. In this phase Ib trial, KW-0761 was used as a cancer immunotherapeutic reagent to deplete Tregs in patients with advanced or recurrent solid CCR4-negative tumors. Thirty-nine patients with solid cancer were treated with KW-0761 at a dose of 0.1 or 1.0 mg/kg. The safety, clinical responses, and effects of Treg depletion were analyzed. Any grade and grade 3\u20134 treatment-related adverse events (AEs) were observed in 36 (92%) and 14 (36%) out of 39 patients, respectively. All treatment-related AEs were manageable. One and 5 patients achieved a partial response and stable disease, respectively, during treatment and were long survivors. The efficient depletion of Treg in peripheral blood was confirmed in both cohorts. Therefore, the administration of KW-0761 was safe, resulting in the depletion of Tregs in peripheral blood and potential immune responses in patients with solid cancer. The combined use of KW-0761 to deplete Tregs and other immunotherapies is a promising approach to augment immune responses.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}, {"subitem_description": "This is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International\nLicense. To view the details of this license, please visit (http://creativecommons.org/licenses/by-nc-nd/4.0/).", "subitem_description_language": "en", "subitem_description_type": "Other"}]}, "item_9_identifier_registration": {"attribute_name": "ID\u767b\u9332", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.83.4.827", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine", "subitem_publisher_language": "en"}]}, "item_9_relation_43": {"attribute_name": "\u95a2\u9023\u60c5\u5831", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/834.html", "subitem_relation_type_select": "URI"}}]}, "item_9_source_id_7": {"attribute_name": "\u53ce\u9332\u7269\u8b58\u5225\u5b50", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "PISSN"}, {"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "EISSN"}]}, "item_access_right": {"attribute_name": "\u30a2\u30af\u30bb\u30b9\u6a29", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Saito, Takuro", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kurose, Koji", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kojima, Takashi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Funakoshi, Takeru", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Sato, Eiichi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Nishikawa, Hiroyoshi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Nakajima, Jun", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Seto, Yasuyuki", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Kakimi, Kazuhiro", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Iida, Shinsuke", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Doki, Yuichiro", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Oka, Mikio", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ueda, Ryuzo", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Wada, Hisashi", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "date": [{"dateType": "Available", "dateValue": "2021-12-03"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "15-2_Saito.pdf", "filesize": [{"value": "548 KB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "application/pdf", "size": 548000.0, "url": {"objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/2001663/files/15-2_Saito.pdf"}, "version_id": "5d109d55-9349-48a2-af88-fcbf107e1397"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "solid cancer patients", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "mogamulizumab", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "regulatory T cells", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "clinical trial", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "CCR4", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors", "subitem_title_language": "en"}]}, "item_type_id": "40001", "owner": "1", "path": ["499/508/509/1638493189962"], "permalink_uri": "https://doi.org/10.18999/nagjms.83.4.827", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2021-12-03"}, "publish_date": "2021-12-03", "publish_status": "0", "recid": "2001663", "relation": {}, "relation_version_is_last": true, "title": ["Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors"], "weko_shared_id": -1}